Portfolio company
Hylomorph
Switzerland · £4.5m raised
Raised
£4.5m
Latest stage
Series B
Rounds recorded
1
Backed by
5 investors
Sectors
About
Hylomorph develops biosynthetic cellulose membranes and pouches to prevent fibrotic encapsulation and post-operative complications for patients receiving cardiac and neurostimulation medical implants.
SourceFunding history · 1
Similar companies
TYBR Health
This company develops a hydrogel system for orthopaedic surgeons to protect tendons and ligaments from internal scarring following surgical procedures.
Nanoflexion
Nanoflexion develops resorbable nanofiber surgical patches to prevent anastomotic leakage and adhesions in patients undergoing gastrointestinal surgery.
Cebiotex
This company develops nanofiber membranes that release anti-tumour agents at surgical sites for oncology patients.
NeuroBionics
This company develops flexible bioelectronic fibers for endovascular neuromodulation to treat neurological and peripheral nerve disorders in patients without requiring invasive open-brain surgery.
Neurobioniocs
The company develops flexible bioelectronic fibers that deliver neuromodulation therapy through blood vessels for patients with neurological disorders.
Hy2Care
This company develops injectable hydrogel implants that facilitate natural cartilage repair for patients with joint injuries to prevent osteoarthritis.
CorInnova
The company develops a minimally invasive cardiac assist device to treat patients with acute heart failure without contacting the blood.
Besthealth4u
This company develops bio-based medical adhesives and wearable sensor patches for wound care and medical device manufacturers to prevent skin injuries and monitor healing.
